Introduction
Discovering that photobiomodulation (PBM) is neuroprotective and has augmentation effects on human neurocognitive functions has been groundbreaking (1). Transcranial PBM with near-infrared light at low irradiance (mW/cm2) and high energy density or fluence (J/cm2) modulates neural functions in a non-thermal way that may have therapeutic effects on various neurological disorders (2). Epilepsy is a brain disorder characterized by a persistent predisposition to generate epileptic seizures and by neurological, cognitive, and psychosocial consequences (3), in addition to postictal antinociception (4–7) and psychiatric comorbidities (8, 9). It is the fourth most common neurological condition in the world. An estimated 70 million people are suffering from some type of epileptic syndrome (10–12). We propose that transcranial PBM may be developed as a new non-invasive therapeutic strategy for epilepsy based on the following: (1) its well-documented mitochondrial mechanism of action relevant to epilepsy, (2) its beneficial neurocognitive effects in humans, and (3) the promising findings from two recent PBM studies in different epilepsy models.
Mitochondrial Dysfunction in Epilepsy
One hypothesis to explain the role of mitochondria in epilepsy is linked to metabolic and energy changes after acute seizures and during chronic epilepsy (13–19). For example, Mueller et al. (14) noted that redox status measured by reduced and oxidized forms of glutathione changes to a more oxidized state in the brain and plasma of epileptic patients. During seizure activity, an acute increase in glucose metabolism and cerebral blood flow is observed in patients with temporal lobe epilepsy (TLE) (17), the most prevalent form of acquired epilepsies (20). In addition, in the study conducted by Vielhaber et al. (19), it was noted that the hypometabolism observed in patients with epilepsy is associated with low levels of mitochondrial N-acetyl aspartate in the CA3 hippocampal subfield. Reduced levels of NAD(P)H were also observed in CA1, CA2, and the subiculum of patients with TLE (21).
Studies performed in laboratory animals have suggested mitochondrial dysfunction and oxidative stress as a key mechanism that follows seizures and contributes to epileptogenesis (20, 22, 23). After seizures there are many changes related to mitochondrial dysfunction and oxidative stress, including an acute increase in mitochondrial oxidative stress, excessive reactive oxygen species (ROS) production, increased oxidation of cellular macromolecules, mitochondrial DNA damage, decreased activity of the electron transport chain (ETC), and increased nitric oxide (NO) generation in the cerebral cortex (24) and hippocampus (22, 25–27). Also, studies have shown a decrease in hippocampal ETC complex I and IV activity and oxidative stress in CA1 and CA3 during chronic epilepsy (15, 16, 18).
In view of this, targeting mitochondrial dysfunction and oxidative stress with PBM may provide a new therapeutic strategy to attenuate seizure activity, impairments linked to neuronal loss, and cognitive function (30).
Mitochondrial Mechanism of Action of Photobiomodulation
Generally, PBM, also known as low-level laser therapy (31), is a non-invasive method that has been shown to modulate neuronal functions, including mitochondrial energy metabolism, proliferation, differentiation, and apoptosis (32, 33). The mechanism of action of PBM primarily involves a photonic biochemical effect on mitochondrial respiration and oxidative stress (34). The major acceptor of red-to-near-infrared photons inside cells is the mitochondrial enzyme cytochrome c oxidase (CCO, also called ETC complex IV), which is considered a fundamental molecule for the action of PBM (35–38).
Photonic oxidation of CCO by transcranial PBM with a near-infrared laser has been demonstrated in vivo in the human brain (39, 40). PBM can induce a series of beneficial cellular events, such as the increase in oxidative phosphorylation for ATP production, increased permeability of the mitochondrial membrane, a brief increase in ROS, and activation of mitochondrial signaling pathways linked to neuroprotection and cell survival (2, 41). In addition, NO released by CCO is able to stimulate ATP production by increasing mitochondrial membrane potential and oxygen consumption (35, 36, 38, 42–44), as well as triggering a physiological hemodynamic response to increasing delivery of oxygen to the human brain (39, 40). However, mechanisms other than CCO may mediate PBM effects under certain conditions, as suggested by the extensive metabolomic effects of PBM on the rat brain (45).
Neurocognitive Effects of Photobiomodulation in Humans
Many human studies have demonstrated the potential of transcranial PBM for the augmentation of neurocognitive functions under several conditions (1, 46–54). Studies using laboratory animals have also documented interesting results of brain PBM (45, 55, 56). For example, our research group submitted aged rats to PBM with transcranial laser for 58 consecutive days and we noted that laser treatment was able to rejuvenate the spatial mnemonic damage of the aged rats and modulate brain levels of inflammatory markers (56). In addition, this same laser treatment protocol increased the brain metabolic pathways of young rats and restored the brain metabolic pathways of aged rats to the levels of younger rats (45).
Studies of Photobiomodulation in Epilepsy Models
Regarding epilepsy, there have been two recent pre-clinical studies showing beneficial effects of PBM in different epilepsy models (Table 1).
Table 1
| Reference | Epilepsy model | Light source | Treatment/Parameters | Outcomes |
|---|---|---|---|---|
| Tsai et al. (28) | Sprague-Dawley rats, Pentylenetetrazole-induced epilepsy | GaAlAs diode laser | Center wavelength: 808 nm Operating mode: continuous Average radiant power: 110 mW Irradiance at aperture: 1.333 W/cm2 Beam spot size: 0.0825 cm2 Exposure duration: 100 s Radiant exposure: 133.3 J/cm2 Number of sessions: 1 Total radiant energy: 11 J | Photobiomodulation attenuated the mean seizure score and reduced the incidence of status epilepticus and mortality. |
| Vogel et al. (29) | Wistar rats, Photothrombotic stroke-induced epilepsy | LED | Center wavelength:780 nm Average radiant power: 10 mW Irradiance at aperture: 0.083 W/cm2 Beam spot size: 0.12 cm2 Exposure duration: 120 s Radiant exposure: 10 J/cm2 Number of sessions: 24 Total radiant energy: 1.20 J | Photobiomodulation reduced both electrographic seizure duration and spikes number in the ipsilateral and contralateral cortices and ventral posteromedial thalamic nucleus. |
Recent evidence of PBM benefits in epilepsy models.
First, Tsai et al. (28) noted that transcranial PBM at wavelength 808 nm was able to attenuate pentylenetetrazole-induced status epilepticus in peripubertal rats. In addition, PBM reduced the apoptotic ratio of parvalbumin-labeled interneurons and alleviated the aberrant extent of parvalbumin-labeled unstained somata of principal cells in the hippocampus. Second, Vogel et al. (29) observed that PBM reduces epileptiform discharges after a stroke (29). They showed that a 780 nm wavelength laser treatment for 2 months after induction of photothrombotic stroke reduced late epileptic electrographic seizures, as well as the number of spikes in the ipsilateral and contralateral cortices and in the ventral posteromedial thalamic nuclei. Although there is a possibility that PBM could trigger epileptic seizures, there is no evidence in support for this, and the two studies evaluating PBM effects on seizure models have found that PBM reduces seizures.
Although these studies present interesting behavioral findings on PBM in epilepsy (28, 29), evidence regarding mitochondrial functions is still lacking. This line of reasoning would be interesting since studies show that mitochondrial damage under various conditions is restored by PBM. Furthermore, this restoration is accompanied by an improvement in behavioral performance (57–59). In fact, PBM increases mitochondrial membrane potential, contributing to an increase in ATP production and a brief increase in ROS (34, 60, 61). In addition, ROS and other mediators of PBM, such as NO and cyclic adenosine monophosphate (cAMP), activate transcription factors. In this sense, after PBM, CCO stimulates ATP synthesis (62, 63). Extracellular ATP is also a neurotransmitter (64) that participates in many signaling pathways, known as purinergic signaling (65). NO acts by stimulation of guanylate cyclase to form cyclic-GMP (cGMP), which induces Ca++ reuptake and the opening of calcium-activated potassium channels via protein kinase G (66). ROS is a mediator that at low concentrations and brief exposures is beneficial, and at high concentrations and long exposure, periods are harmful (67). When induced by PBM, ROS activates nuclear factor kappa B (NF-kB), which contributes to the increase in gene transcription, and consequently cellular processes, such as proliferation, migration, and cell death (60). cAMP can down-regulate the LPS-induced TNF-α synthesis at the transcriptional level (68–70). Also, cAMP exerts its cellular effects through the signaling of protein kinase A (PKA), cyclic nucleotide-gated channels (CNGC), and exchange proteins directly activated by cAMP (Epac) (71–73). Together, the upregulation of mitochondrial respiration that triggers these metabolic signaling cascades suggests that the long-term effects of PBM might be beneficial to treat the mitochondrial deficits found in epilepsy.
Although these results are promising, much more evidence of the effects of PBM on the epileptic brain is needed. When this evidence becomes available, then PBM may be translated to the clinic, but the evidence is too limited at this time.
Conclusion
Transcranial PBM may treat the mitochondrial dysfunction in epilepsy by upregulating CCO, which is the terminal enzyme in mitochondrial respiration. This mitochondrial mechanism of action of PBM might benefit epilepsy because transcranial PBM is neuroprotective and improves human neurocognitive functions affected by epilepsy. This fascinating new intervention is safe and non-invasive and should be tested further to confirm if augmenting neuronal mitochondrial respiration is a neurotherapeutic strategy for epilepsy.
Funding
This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (grants 1996/8574-9 and 2009/00668-6), Conselho Nacional de Pesquisa e Desenvolvimento Tecnológico (CNPq) (grant 474425/2008-8) and Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES) (AUX-PE-PNPD 2400/2009; grant 23038.027801/2009-37). None of these organizations had a role in the study design, the collection, analysis and interpretation of the data, the writing of the report, or the decision to submit the paper for publication. FC was financially supported by FAPESP (Postdoctoral fellowship grant 2021/06473-4). NC Coimbra is a researcher from CNPq (PQ1A-level grants 301905/2010-0 and 301341/2015-0; PQ2-level grant 302605/2021-5). FG-L was supported by the Oskar Fischer Project Fund.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
Gonzalez-LimaF. Neuroprotection and Neurocognitive augmentation by Photobiomodulation. In: OprisI.LebedevM. A.CasanovaM. F. (Eds), Modern Approaches to Augmentation of Brain Function. Cham: Springer. (2021). p. 165–207. 10.1007/978-3-030-54564-2_9
2.
RojasJCGonzalez-LimaF. Neurological and psychological applications of transcranial lasers and LEDs. Biochem Pharmacol. (2013) 86:447–57. 10.1016/j.bcp.2013.06.012
3.
FisherRSCrossJHFrenchJAHigurashiNHirschEJansenFEet al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. (2017) 58:522–30. 10.1111/epi.13670
4.
CoimbraNCFreitasRLSavoldiMCastro-SouzaCSegatoENKishiRet al. Opioid neurotransmission in the post-ictal analgesia: involvement of μ1-opioid receptor. Brain Res. (2001) 903:216–21. 10.1016/S0006-8993(01)02366-6
5.
FreitasRLFerreiraCMRRibeiroSJCarvalhoADElias-FilhoDHGarcia-CairascoNet al. Intrinsic neural circuits between dorsal midbrain neurons that control fear-induced responses and seizure activity and nuclei of the pain inhibitory system elaborating postictal antinociceptive processes: a functional neuroanatomical and neuropharmacological study. Exp Neurol. (2005) 191:225–42. 10.1016/j.expneurol.2004.10.009
6.
FreitasRLBassiGSde OliveiraAMCoimbraNC. Serotonergic neurotransmission in the dorsal raphe nucleus recruits in situ 5-HT2A/2C receptors to modulate the post-ictal antinociception. Exp Neurolol. (2008) 213:410–8. 10.1016/j.expneurol.2008.07.003
7.
FreitasRLFerreiraCMRUrbinaMAMariñoAUCarvalhoADButeraGet al. 5-HT1A/1B, 5-HT6, and 5-HT7 serotonergic receptors recruitment in tonic-clonic seizure-induced antinociception: role of dorsal raphe nucleus. Exp Neurolol. (2009) 217:16–24. 10.1016/j.expneurol.2009.01.003
8.
FiordelliEBeghiEBogliunGCrespiV. Epilepsy and psychiatric disturbance. A cross-sectional study. Br J Psychiat. (1993) 163:446–50. 10.1192/bjp.163.4.446
9.
JakobsenAVElklitA. Post-traumatic stress disorder (PTSD) symptoms in children with severe epilepsy. Epilepsy Behav. (2021) 122:108217. 10.1016/j.yebeh.2021.108217
10.
ReynoldsEH. Introduction: epilepsy in the world. Epilepsia. (2002) 43:1–3. 10.1046/j.1528-1157.43.s.6.1.x
11.
NgugiAKBottomleyCKleinschmidtISanderJWNewtonCR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. (2010) 51:883–90. 10.1111/j.1528-1167.2009.02481.x
12.
BellGSNeliganASanderJW. An unknown quantity—the worldwide prevalence of epilepsy. Epilepsia. (2014) 55:958–62. 10.1111/epi.12605
13.
KunzWSKudinAPVielhaberSBlümckeIZuschratterWSchrammJet al. Mitochondrial complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy. Ann Neurol. (2000) 48:766–73. 10.1002/1531-8249(200011)48:5<766::AID-ANA10>3.0.CO;2-M
14.
MuellerSGTrabesingerAHBoesigerPWieserHG. Brain glutathione levels in patients with epilepsy measured by in vivo 1H-MRS. Neurology. (2001) 57:1422–7. 10.1212/WNL.57.8.1422
15.
KudinAPKudinaTASeyfriedJVielhaberSBeckHElgerCEet al. Seizure-dependent modulation of mitochondrial oxidative phosphorylation in rat hippocampus. Eur J Neurosci. (2002) 15:1105–14. 10.1046/j.1460-9568.2002.01947.x
16.
ChuangYCChangAYLinJWHsuSPChanSH. Mitochondrial dysfunction and ultrastructural damage in the hippocampus during kainic acid–induced status epilepticus in the rat. Epilepsia. (2004) 45:1202–9. 10.1111/j.0013-9580.2004.18204.x
17.
KawaiNMiyakeKKurodaYYamashitaSNishiyamaYMondenTet al. Magnetic resonance imaging and positron emission tomography findings in status epilepticus following severe hypoglycemia. Ann Nucl Med. (2006) 20:371–6. 10.1007/BF02987250
18.
GaoJChiZFLiuXWShanPYWangR. Mitochondrial dysfunction and ultrastructural damage in the hippocampus of pilocarpine-induced epileptic rat. Neurosci Lett. (2007) 411:152–7. 10.1016/j.neulet.2006.10.022
19.
VielhaberSNiessenHGDebska-VielhaberGKudinAPWellmerJKaufmannJet al. Subfield-specific loss of hippocampal N-acetyl aspartate in temporal lobe epilepsy. Epilepsia. (2008) 49:40–50. 10.1111/j.1528-1167.2007.01280.x
20.
RowleySPatelM. Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. Free Radic Biol Med. (2013) 62:121–31. 10.1016/j.freeradbiomed.2013.02.002
21.
KannOKovácsRNjuntingMBehrensCJOtáhalJLehmannTNet al. Metabolic dysfunction during neuronal activation in the ex vivo hippocampus from chronic epileptic rats and humans. Brain. (2005) 128:2396–407. 10.1093/brain/awh568
22.
WaldbaumSLiangLPPatelM. Persistent impairment of mitochondrial and tissue redox status during lithium-pilocarpine-induced epileptogenesis. J Neurochem. (2010) 115:1172–82. 10.1111/j.1471-4159.2010.07013.x
23.
PuttacharySSharmaSStarkSThippeswamyT. Seizure-induced oxidative stress in temporal lobe epilepsy. Biomed Res Int. (2015) 2015:745613. 10.1155/2015/745613
24.
TejadaSSuredaARocaCGamundiAEstebanS. Antioxidant response and oxidative damage in brain cortex after high dose of pilocarpine. Brain Res Bull. (2007) 71:372–5. 10.1016/j.brainresbull.2006.10.005
25.
BruceAJBaudryM. Oxygen free radicals in rat limbic structures after kainate-induced seizures. Free Radic Biol Med. (1995) 18:993–1002. 10.1016/0891-5849(94)00218-9
26.
LiangLPHoYSPatelM. Mitochondrial superoxide production in kainate-induced hippocampal damage. Neuroscience. (2000) 101:563–70. 10.1016/S0306-4522(00)00397-3
27.
JarrettSGLiangLPHellierJLStaleyKJPatelM. Mitochondrial DNA damage and impaired base excision repair during epileptogenesis. Neurobiol Dis. (2008) 30:130–8. 10.1016/j.nbd.2007.12.009
28.
TsaiCMChangSFChangH. Transcranial photobiomodulation attenuates pentylenetetrazole-induced status epilepticus in peripubertal rats. J Biophotonics. (2020) 13:e202000095. 10.1002/jbio.202000095
29.
VogelDDOrtiz-VillatoroNNde FreitasLAimbireFScorzaFAAlbertiniRet al. Repetitive transcranial photobiomodulation but not long-term omega-3 intake reduces epileptiform discharges in rats with stroke-induced epilepsy. J Biophotonics. (2021) 14:e202000287. 10.1002/jbio.202000287
30.
Pearson-SmithJNPatelM. Metabolic dysfunction and oxidative stress in epilepsy. Int J Mol Sci. (2017) 18:2365. 10.3390/ijms18112365
31.
AndersJJLanzafameRJAranyPR. Low-level light/laser therapy versus photobiomodulation therapy. Photomed Laser Surg. (2015) 33:183–4. 10.1089/pho.2015.9848
32.
RojaJCGonzalez-LimaF. Low-level light therapy of the eye and brain. Eye and Brain. (2011) 3:49. 10.2147/eb.s21391
33.
ChungHDaiTSharmaSKHuangYYCarrollJDHamblinMR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. (2012) 40:516–33. 10.1007/s10439-011-0454-7
34.
Gonzalez-LimaFBarksdaleBRRojasJC. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol. (2014) 88:584–93. 10.1016/j.bcp.2013.11.010
35.
KaruTI. Molecular mechanism of the therapeutic effect of low-intensity laser radiation. Lasers Life Sci. (1988) 2:53–74.
36.
KaruTI. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. J Photochem Photobiol B. (1999) 49:1–17. 10.1016/S1011-1344(98)00219-X
37.
KaruTIPyatibratLVKalendoGS. Photobiological modulation of cell attachment via cytochrome c oxidase. Photochem Photobiol Sci. (2004) 3:211–6. 10.1039/b306126d
38.
KaruTIKolyakovSF. Exact action spectra for cellular responses relevant to phototherapy. Photomed Laser Surg. (2005) 23:355–61. 10.1089/pho.2005.23.355
39.
WangXTianFReddyDDNalawadeSSBarrettDWGonzalez-LimaFet al. Up-regulation of cerebral cytochrome-c-oxidase and hemodynamics by transcranial infrared laser stimulation: a broadband near-infrared spectroscopy study. J Cereb Blood Flow Metab. (2017) 37:3789–802. 10.1177/0271678X17691783
40.
SaucedoCLCourtoisECWadeZSKelleyMNKheradbinNBarrettDWet al. Transcranial laser stimulation: Mitochondrial and cerebrovascular effects in younger and older healthy adults. Brain Stimul. (2021) 14:440–9. 10.1016/j.brs.2021.02.011
41.
dos Santos CardosoFMansurFCAraújoBHGonzalez-LimaFGomes da SilvaS. Photobiomodulation improves the inflammatory response and intracellular signaling proteins linked to vascular function and cell survival in the brain of aged rats. Mol Neurobiol. (2021) 59:420–8. 10.1007/s12035-021-02606-4
42.
PassarellaSCasamassimaEMolinariSPastoreDQuagliarielloECatalanoIMet al. Increase of proton electrochemical potential and ATP synthesis in rat liver mitochondria irradiated in vitro by helium-neon laser. FEBS Lett. (1984) 175:95–9. 10.1016/0014-5793(84)80577-3
43.
HamblinMR. The role of nitric oxide in low level light therapy. in Biomedical Optics (BiOS). International Society for Optics and Photonics. (2008). 6846:684602:684614. 10.1117/12.764918
44.
LaneN. Cell biology: power games. Nature. (2006) 443:901–904. 10.1038/443901a
45.
dos Santos CardosoFDos SantosJCGonzalez-LimaFAraújoBHLopes-MartinsRÁGomes da SilvaS. Effects of chronic photobiomodulation with transcranial near-infrared laser on brain metabolomics of young and aged rats. Mol Neurobiol. (2021) 58:2256–2268. 10.1007/s12035-020-02247-z
46.
BarrettDWGonzalez-LimaF. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans. Neuroscience. (2013) 230:13–23. 10.1016/j.neuroscience.2012.11.016
47.
DisnerSGBeeversCGGonzalez-LimaF. Transcranial laser stimulation as neuroenhancement for attention bias modification in adults with elevated depression symptoms. Brain Stimul. (2016) 9:780–7. 10.1016/j.brs.2016.05.009
48.
HwangJCastelliDMGonzalez-LimaF. Cognitive enhancement by transcranial laser stimulation and acute aerobic exercise. Lasers Med Sci. (2016) 31:1151–60. 10.1007/s10103-016-1962-3
49.
VargasEBarrettDWSaucedoCLHuangLDAbrahamJATanakaHet al. Beneficial neurocognitive effects of transcranial laser in older adults. Lasers Med Sci. (2017) 32:1153–62. 10.1007/s10103-017-2221-y
50.
BlancoNJMaddoxWTGonzalez-LimaF. Improving executive function using transcranial infrared laser stimulation. J Neuropsychol. (2017) 11:14–25. 10.1111/jnp.12074
51.
BlancoNJSaucedoCLGonzalez-LimaF. Transcranial infrared laser stimulation improves rule-based, but not information-integration, category learning in humans. Neurobiol Learn Mem. (2017) 139:69–75. 10.1016/j.nlm.2016.12.016
52.
SaltmarcheAENaeserMAHoKFHamblinMRLimL. Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: case series report. Photomed Laser Surg. (2017) 35:432–41. 10.1089/pho.2016.4227
53.
HolmesEBarrettDWSaucedoCLO'ConnorPLiuHGonzalez-LimaF. Cognitive enhancement by transcranial photobiomodulation is associated with cerebrovascular oxygenation of the prefrontal cortex. Front Neurosci. (2019) 13:1129. 10.3389/fnins.2019.01129
54.
O'DonnellCMBarrettDWFinkLHGarcia-PittmanECGonzalez-LimaF. Transcranial infrared laser stimulation improves cognition in older bipolar patients: proof of concept study. J Geriatr Psychiatry Neurol. (2021) 35:321–32. 10.1177/0891988720988906
55.
OronAOronUStreeterJTaboadaLDAlexandrovichATrembovlerVet al. Low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. J Neurotrauma. (2007) 24:651–6. 10.1089/neu.2006.0198
56.
CardosoFDde Souza Oliveira TavaresCAraujoBHMansurFLopes-MartinsRAGomes da SilvaS. Improved spatial memory and neuroinflammatory profile changes in aged rats submitted to photobiomodulation therapy. Cell Mol Neurobiol. (2021) 1–12. 10.1007/s10571-021-01069-4
57.
SalehpourFFarajdokhtFCassanoPSadigh-EteghadSErfaniMHamblinMRet al. Near-infrared photobiomodulation combined with coenzyme Q10 for depression in a mouse model of restraint stress: reduction in oxidative stress, neuroinflammation, and apoptosis. Brain Res Bull. (2019) 144:213–22. 10.1016/j.brainresbull.2018.10.010
58.
SalehpourFAhmadianNRastaSHFarhoudiMKarimiPSadigh-EteghadS. Transcranial low-level laser therapy improves brain mitochondrial function and cognitive impairment in D-galactose–induced aging mice. Neurobiol Aging. (2017) 58:140–50. 10.1016/j.neurobiolaging.2017.06.025
59.
ZhangZShenQWuXZhangDXingD. Activation of PKA/SIRT1 signaling pathway by photobiomodulation therapy reduces Aβ levels in Alzheimer's disease models. Aging Cell. (2020) 19:e13054. 10.1111/acel.13054
60.
ChenACAranyPRHuangYYTomkinsonEMSharmaSKKharkwalGBet al. Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS ONE. (2011) 6:e22453. 10.1371/journal.pone.0022453
61.
SuskiJMLebiedzinskaMBonoraMPintonPDuszynskiJWieckowskiMR. Relation between mitochondrial membrane potential and ROS formation. In: Methods Mol. Biol. (2012) 810:183–205. 10.1007/978-1-61779-382-0_12
62.
FerraresiCHamblinMRParizottoNA. Low-level laser (light) therapy (LLLT) on muscle tissue: performance, fatigue and repair benefited by the power of light. Photonics Lasers Med. (2012) 1:267–86. 10.1515/plm-2012-0032
63.
FerraresiCKaippertBAvciPHuangYYde SousaMVBagnatoVSet al. Low-level laser (light) therapy increases mitochondrial membrane potential and ATP synthesis in C2C12 myotubes with a peak response at 3–6 h. Photochem Photobiol. (2015) 91:411–6. 10.1111/php.12397
64.
BurnstockG. Purinergic nerves and receptors. Prog Biochem Pharmacol. (1980) 16:141–54.
65.
DubyakGR. Signal transduction by P2-purinergic receptors for extracellular ATP. Am J Respir Cell Mol Biol. (1991) 4:295–300. 10.1165/ajrcmb/4.4.295
66.
MuradF. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci Rep. (2004) 24:452–74. 10.1007/s10540-005-2741-8
67.
Popa-WagnerAMitranSSivanesanSChangEBugaAM. ROS and brain diseases: the good, the bad, and the ugly. Oxidat Med Cell Longev. (2013):963520. 10.1155/2013/963520
68.
SpenglerRNSpenglerMLLincolnPRemickDGStrieterRMKunkelSL. Dynamics of dibutyryl cyclic AMP-and prostaglandin E2-mediated suppression of lipopolysaccharide-induced tumor necrosis factor alpha gene expression. Infect Immun. (1989) 57:2837–41. 10.1128/iai.57.9.2837-2841.1989
69.
TannenbaumCSHamiltonTA. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J Immunol. (1989) 142:1274–80.
70.
PrabhakarULipshutzDBartusJOSlivjakMJSmithEFIIILeeJCet al. Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol. (1994) 16:805–816. 10.1016/0192-0561(94)90054-X
71.
ZagottaWNSiegelbaumSA. Structure and function of cyclic nucleotide-gated channels. Annu Rev Neurosci. (1996) 19:235–63. 10.1146/annurev.ne.19.030196.001315
72.
BosJL. Epac: a new cAMP target and new avenues in cAMP research. Nature reviews. Molec Cell Biol. (2003) 4:733–8. 10.1038/nrm1197
73.
TaskenKAandahlEM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. (2004) 84:137–67. 10.1152/physrev.00021.2003
Summary
Keywords
photobiomodulation, low-level laser therapy, epilepsy, seizure, mitochodria, oxidative stress
Citation
Cardoso FS, Gonzalez-Lima F and Coimbra NC (2022) Mitochondrial Photobiomodulation as a Neurotherapeutic Strategy for Epilepsy. Front. Neurol. 13:873496. doi: 10.3389/fneur.2022.873496
Received
10 February 2022
Accepted
23 May 2022
Published
16 June 2022
Volume
13 - 2022
Edited by
Jonathan Stone, The University of Sydney, Australia
Reviewed by
Michael Hamblin, University of Johannesburg, South Africa; John Mitrofanis, Université Grenoble Alpes, France
Updates
Copyright
© 2022 Cardoso, Gonzalez-Lima and Coimbra.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fabrízio dos Santos Cardoso fabrizioscardoso@yahoo.com.brFrancisco Gonzalez-Lima gonzalezlima@utexas.edu
This article was submitted to Epilepsy, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.